a current prediction, page-119

Immutep Successfully Achieves Commercial Scale in Manufacturing of
Eftilagimod Alpha
First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein
Completed by WuXi Biologics
SYDNEY, AUSTRALIA – 8 December, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or
“the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer
and autoimmune disease, today announces the successful scale-up of the manufacturing of its lead product
candidate eftilagimod alpha (“efti” or “IMP321”), a first-in-class soluble LAG-3 protein, with the completion
of a 2,000L manufacturing run.
In preparation for late-stage clinical trials and commercial production, Immutep has been working with WuXi
Biologics to increase the efti manufacturing process from 200L to 2,000L capacity single-use bioreactors at
the manufacturing plant in Wuxi city, China. The first 2,000L manufacturing run has been performed
successfully with all predefined release criteria met.